Yahoo
    Warsaw - Delayed Quote PLN

    Sygnity S.A. (SGN.WA)

    97.10 +1.10 (+1.15%)
    As of 10:47:58 AM GMT+1. Market Open.
    Loading Chart for SGN.WA
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Mayr-Melnhof surges 16% on €2.4 billion deal to sell packaging stake to KPS

    Mayr-Melnhof surges 16% on €2.4 billion deal to sell packaging stake to KPS
    Investing.com 53m ago
    SES (ENXTPA:SESG) Stock May Still Be Undervalued On Reiterated 2026 Outlook

    SES (ENXTPA:SESG) Stock May Still Be Undervalued On Reiterated 2026 Outlook
    Simply Wall St. 56m ago
    FY 2026 Guidance Upgraded

    FY 2026 Guidance Upgraded
    GlobeNewswire 1h ago
    Jeudan (CPSE:JDAN) Stock May Be Hard To Call After A 22% Fall

    Jeudan (CPSE:JDAN) Stock May Be Hard To Call After A 22% Fall
    Simply Wall St. 1h ago
    Flexible Solutions International (FSI) Surges 8.9%: Is This an Indication of Further Gains?

    Flexible Solutions International (FSI) Surges 8.9%: Is This an Indication of Further Gains?
    Zacks 2h ago
    Agfa-Gevaert in Q3 2026: Executing Transformation Despite Challenging Markets

    Agfa-Gevaert in Q3 2026: Executing Transformation Despite Challenging Markets
    GlobeNewswire 3h ago
    ValueAct Issues Open Letter to Takara Holdings Shareholders Explaining Request for an Extraordinary General Meeting

    ValueAct Issues Open Letter to Takara Holdings Shareholders Explaining Request for an Extraordinary General Meeting
    Business Wire 3h ago
    Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer

    Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer
    Zacks 4h ago
    Will Buyback Plan Change Nisshin Seifun's (TSE:2002) Narrative

    Will Buyback Plan Change Nisshin Seifun's (TSE:2002) Narrative
    Simply Wall St. 5h ago
    Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...

    Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...
    Business Wire 8h ago
    Daido Steel (TSE:5471) Stock Could Be 44% Overvalued As Earnings Guidance Rises

    Daido Steel (TSE:5471) Stock Could Be 44% Overvalued As Earnings Guidance Rises
    Simply Wall St. 9h ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: